Ligand Pharmaceuticals (LGND) Faces A Valuation Test After Expanding Ryjunea Royalties

Ligand Pharmaceuticals (LGND) recently agreed to acquire full royalty rights on Ryjunea net sales in Europe, the Middle East, and Africa. This move ties future revenue directly to this pediatric myopia treatment.

Ligand Pharmaceuticals’ latest Ryjunea royalty deal comes at a time when the share price has shown strong momentum this year. The stock’s year to date share price return of 57.06% and 1 year total shareholder return of 79.05% sit alongside a very large 3 year total shareholder return, suggesting that investors have been steadily reassessing both the growth potential and the risk profile of the business.

Scan how the Ryjunea royalty move compares with other potential breakout ideas by reviewing the hand picked 16 high quality undiscovered gems across the market.

Ligand Pharmaceuticals now faces a sharper question. Is the Ryjunea royalty deal a sign that the underlying royalty engine is gaining depth, or has sentiment simply sprinted ahead of what the business is worth today?

Most Popular Narrative: 13% Undervalued

Against the last close of $298.58, the most followed narrative pegs Ligand Pharmaceuticals at a fair value of $342.82, using a 7.24% discount rate and a detailed view of future royalties and margins.

Strong revenue and earnings growth are expected as Ligand broadens its high-margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late-stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long-term cash flow predictability.

See why 6 investors see Ligand Pharmaceuticals as 13% undervalued.

Result: Fair Value of $342.82 (UNDERVALUED)

Still, the bullish Ligand Pharmaceuticals story can crack if drug pricing pressure bites into key royalties, or if just one major partnered therapy underdelivers against current expectations.

Find out about the key risks to this Ligand Pharmaceuticals narrative.

Another View on Ligand Pharmaceuticals’ Valuation

The popular story frames Ligand Pharmaceuticals as about 13% undervalued based on future royalties and cash flows. A simple P/E check tells a tougher story. LGND trades at 30.2x earnings, compared with a 16x US Pharmaceuticals sector average and a fair ratio of 22x from regression work.

That gap implies investors are already paying a premium for this royalty model, even though the fair ratio points to a level the multiple could drift toward if enthusiasm cools. How comfortable are you with that valuation stretch?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Whether Ligand Pharmaceuticals presents a strong story or stretched optimism, it is important to review the underlying numbers and sentiment for yourself, starting with 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ligand Pharmaceuticals?

If Ligand Pharmaceuticals has sharpened your appetite for focused royalty stories, do not stop here. Broader opportunities could sit just outside your current watchlist.

Scan fresh value candidates by reviewing the 30 high quality undervalued stocks that pair compressed valuations with solid underlying businesses.

Balance potential upside with staying power by checking the list of solid balance sheet and fundamentals (23 results) that prioritize financial strength and cleaner balance sheets.

Reduce portfolio strain from wild swings by focusing on the 31 resilient stocks with low risk scores that emphasise resilience and more predictable risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com